Novel Device Approval Numbers Drop Sharply, But All is Well, FDA's Shuren Says

article image

The FDA review program and US medtech innovation ecosystem remain strong, despite a sharp drop in the number of novel devices approved by FDA in 2019, says Jeff Shuren, the agency’s device director. A look at the FDA trend numbers crunched by Market Pathways, and our discussion with Shuren about the state of the review program and what to expect in 2020.

After four record-setting years, the number of novel devices approved by FDA fell by more than 30% in 2019. But, in an interview, FDA device center director Jeff Shuren, MD, says the decline does not signal a problem with the agency’s review process or the US medtech pipeline.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: